Bridging the Gap: Conference Workbook [International Conference on AIDS (12th: 1994: Geneva, Switzerland)]

Monday, June 29

I. PSSA
11126 Compensatory point mutations in the HIV gag region that are distal
from deletion mutations in the dimerization initiation site can restore
viral replication
MarkA. Wainberg*; Chen Liang; Liwei Rong, Canada
11127 Inactivation and reactivation of integrated HIV-1 genomes
in cell culture by CpG methylation
Johannes Loewer*; Mareike Marschall; R. Loewer; S. Bergmann,
Germany
11128 Potential protective effect of antibodies to P66 during the course
of HIV-1 infection
Philippe Moja*; V. Cheynet; T. Bourlet; F. Mallet; F. Lucht;
B. Pozzetto; C Genin, France
11129 Heat shock modulation of HIV-1 infection
Edward V. Karamov*; A.N. Yudin; M.B. Evgen'ev; A. V. Abelian;
G. V. Kornelayeva; A. V. Kozlova; Kh.A. Ulmasov, Russia
11130 HIV-1 Vifis an endogenous inhibitor of HIV-1 protease and peptide
derivatives of Vif inhibit Gag-Pol processing and HIV-1 replication
David Volsky*; P. Sova; M. Simm; C Krachmarov; T. Muir;
RJ. Potash, USA
11131 The impact of interactions between NC, viral RNA and protease of
HIV-1 on infectious virion assembly
Susan Erickson-Viitanen*; D. Ozturk; H.K. Choi; R. Tritch; R. Meade;
A. Draganescu; P. Cawood, USA
11132 Transmission of immature HIV-1 during protease inhibitor treatment or
by mutants in the viral protease
Mary Jane Potash*; C. Krachmarov; G. Bentsman; D.J. Volsky, USA
11133 HIV maturation and stability in the presence of protease inhibitors
in vitro
Richard M. Donovan*; D.A. Friedman; H.J. Caceres; D.M. Baxa;
CE. Bush; N.P. Markowitz, USA
11134 Identification ofa minimum HIV-1 gag sequence required for
particle assembly
Chin-Tien Wang, Taiwan
11135 Role of HIV-1 capsid phosphorylation in viral infection
Christine Cartier*; P. Sivard; C. Tranchat; C. Desgranges; V. Boyer, France
11136 Production and characterization of core like particles (CLP) by
expression of the HIV-1 gag gene in a Baculovirus system
Eric Saman*; I. Ottevaere; M. Vanden Haesevelde; M. Cornelissen;
K. Devos, Belgium
11137 The role of the cytoskeleton of HIV-infected cells as the transportation
system of viral structural proteins
Ichiro Takahashi*; M. Takama; K. Ushijima; Y. Nonomura;
H. Hoshino, Japan
11138 Immunocytochemical localizations of HIV-1 gag proteins and
formation of 0-shaped virion particles associate with p17
Jaang-Jiun Wang*; C. T Chiou; RH. Chiang; B. Hortor; L. Ratner, ROC
11139 Quantitative molecular analysis of RNA expression of HIV-infected
T cell using high density oligonucleotide arrays
Jacques Corbeil*; T.R. Gingeras; G. Mamtora; D. Huang;
D.D. Richman, USA

11140 Identification and characterisation of nef deleted viruses from
three long term nonprogressors
David Rhodes*; L. Ashton; A. Solomon; A. Carr; D. Cooper;
J. Kaldor; N. Deacon, Australia
11141 Cell cycle G2 arrest by HIV-1 Vpr is not responsible for Vpr-induced
cell death
YuqiZhao*; R.T. Elder; M. Yu; M.Z. Chen, USA
11142 T cell apoptosis in mice transgenic for HIV-1 Vpr
Yoichiro Iwakura*; Tamaki Maiyao, Japan
11143 Sydney blood bank cohort virus evolution and quantitation
of virus attenuation
David Rhodes*; A. Solomon; N. Deacon, Australia
11144 Molecular mechanisms of HIV-1 nuclear import:MA andVprare
the key regulators
Michael Bukrinsky*; S. Popov, USA
11145 The HIV-1 nef protein induces CD4+ T cell apoptosis through
functional upregulation of the CD95/CD95L pathway
Yves Collette*; G. Zauli; D. Gibellini; P. Secchiero; H. Dutartre;
D. Olive; S. Capitani, France
11146 Diversification of nefand vpu in six hemophilia B patients after
clonal HIV-1 infection
Astrid Klein*; B. Kupfer; H.H. Brackmann; J.K. Rockstroh; P. Kasper;
B. Matz; R. Kaiser, Germany
11147 Positive selection ofVpr in human immunodeficiency
virus type 1 infection and disease progression
Nitin Saksena*; B. Wang; R. Joswiak, Australia
11148 Diversity of HIV-1 long terminal repeat (LTR) sequences derived
from Mexican donors at different stages of infection
Carmen Soler Claudin*; Victor Raul Gomez Roman;
M.C. Basualdo Sigales, Mexico
11149 Nef gene variability role in HIV-infection development
VitaliZverev*; G.R. Matsevich; K.A. Ryzhov; O.A. Borzykh;
L.L. Sukhanova; A.A. Grinev; V.A. Goltsov, Russia
11150 Latent viral reservoirs in patients on highly active antiretroviral
therapy: Implications for virus eradication
Diana Finzi*;J. Gallant; K. Chadwick; J. Margolick; R.F. Siliciano, USA
11151 Seminal cell-associated viral transcriptional activity and the level of
seminal chemokines in the shedding of HIV-1 in semen
PhalguniGupta* B.K. Patterson; C.R. Rinaldo;M. Ding; K. Kulka;
W. Buchanan; L. Kingsley, USA
11152 Slow proviral DNA reduction in patients on triple drug therapy
and rapid viral rebound upon stopping therapy
Richard Paul Harrigan*; J.S.G. Montaner; C. Christopherson;
S. Kwok;J. Sninsky; M. Harris; B. Conway, Canada
11153 Modeling the sources for persistent HIV load in patients receiving
HAART: Evidence for a drug sanctuary compartment
Avidan U. Neumann*; A. Mallet; V. Calvez; T Li;R. Tubiana;
C. Katlama; B. Autran, Israel
11154 Viral dynamics in HIV-infected patients: Correlation with

Host-Specific factors and virological failure
Hulin Wu*; D.R. Kuritzkes; M.S. Clair; G. Spear; E. Connick;
A. Landay; M.M. Lederman, USA

22

12th World AIDS Conference Geneva